Treatment of dystonia occurring in parkinsonian syndromes by botulinum toxin.
Limousin
P
P
Department of Clinical and Biological Neurosciences, Joseph Fourier University, Grenoble, France.
Memin
B
B
Pollak
P
P
D000368:Aged; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004421:Dystonia / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010302:Parkinson Disease, Secondary / Q000188:drug therapy*; D016896:Treatment Outcome
D019274:Botulinum Toxins, Type A